228 related articles for article (PubMed ID: 29845398)
1. Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
Louhichi T; Ziadi S; Saad H; Dhiab MB; Mestiri S; Trimeche M
Breast Cancer; 2018 Nov; 25(6):698-705. PubMed ID: 29845398
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma.
Han SA; Jang JH; Won KY; Lim SJ; Song JY
Pathol Res Pract; 2017 Aug; 213(8):956-963. PubMed ID: 28687160
[TBL] [Abstract][Full Text] [Related]
4. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.
Park SY; Kwon HJ; Choi Y; Lee HE; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Mod Pathol; 2012 Feb; 25(2):185-96. PubMed ID: 22037257
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
7. Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas.
Henderson T; Chen M; Darrow MA; Li CS; Chiu CL; Monjazeb AM; Murphy WJ; Canter RJ
J Surg Res; 2018 Mar; 223():207-214. PubMed ID: 29433875
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
[TBL] [Abstract][Full Text] [Related]
11. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer.
Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
Neoplasma; 2014; 61(3):352-62. PubMed ID: 24824938
[TBL] [Abstract][Full Text] [Related]
12. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma.
Rabinovich I; Sebastião APM; Lima RS; Urban CA; Junior ES; Anselmi KF; Elifio-Esposito S; De Noronha L; Moreno-Amaral AN
Eur J Histochem; 2018 Sep; 62(3):. PubMed ID: 30362671
[TBL] [Abstract][Full Text] [Related]
14. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
16. Expression of cancer stem cell markers in breast phyllodes tumor.
Kim SI; Koo JS
Cancer Biomark; 2020; 29(2):235-243. PubMed ID: 32675396
[TBL] [Abstract][Full Text] [Related]
17. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
18. The combination of aldehyde dehydrogenase 1 (ALDH1) and CD44 is associated with poor outcomes in endometrial cancer.
Huang HH; Wang YC; Chou YC; Yu MH; Chao TK
PLoS One; 2018; 13(10):e0206685. PubMed ID: 30372483
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.
DA Cruz Paula A; Marques O; Sampaio R; Rosa A; Garcia J; Rêma A; DE Fátima Faria M; Silva P; Vizcaíno R; Lopes C
Anticancer Res; 2016 Sep; 36(9):4629-38. PubMed ID: 27630305
[TBL] [Abstract][Full Text] [Related]
20. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.
Ohi Y; Umekita Y; Yoshioka T; Souda M; Rai Y; Sagara Y; Sagara Y; Sagara Y; Tanimoto A
Histopathology; 2011 Oct; 59(4):776-80. PubMed ID: 22014057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]